1. Home
  2. LPA vs MGNX Comparison

LPA vs MGNX Comparison

Compare LPA & MGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

LPA

Logistic Properties of the Americas

N/A

Current Price

$2.84

Market Cap

98.0M

Sector

N/A

ML Signal

N/A

Logo MacroGenics Inc.

MGNX

MacroGenics Inc.

HOLD

Current Price

$4.18

Market Cap

220.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LPA
MGNX
Founded
2013
2000
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
98.0M
220.6M
IPO Year
2023
2013

Fundamental Metrics

Financial Performance
Metric
LPA
MGNX
Price
$2.84
$4.18
Analyst Decision
Buy
Analyst Count
0
5
Target Price
N/A
$5.00
AVG Volume (30 Days)
19.1K
1.3M
Earning Date
05-13-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$149,500,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$3.19
P/E Ratio
$11.25
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.04
$1.19
52 Week High
$8.34
$4.64

Technical Indicators

Market Signals
Indicator
LPA
MGNX
Relative Strength Index (RSI) 38.77 59.77
Support Level $2.56 $1.48
Resistance Level $3.33 N/A
Average True Range (ATR) 0.25 0.32
MACD -0.06 0.02
Stochastic Oscillator 14.73 73.10

Price Performance

Historical Comparison
LPA
MGNX

About LPA Logistic Properties of the Americas

Logistic Properties of the Americas is a fully-integrated, internally managed real estate company that develops, owns, and manages a diversified portfolio of warehouse logistics assets in Central America and South America. It focuses on modern Class A logistics real estate in high-growth and high-barrier-to-entry markets that are undersupplied and have low penetration rates. The company has four operating segments, based on geographic regions, consisting of Colombia, Peru, Mexico and Costa Rica. The company generates the majority of its revenue from the Costa Rica geographical segment.

About MGNX MacroGenics Inc.

Macrogenics Inc is a clinical-stage biopharmaceutical company focused on developing antibody-based therapeutics for the treatment of cancer. The company is currently developing therapeutics utilizing multiple modalities, including antibody-drug conjugates (ADCs) and multi-specific antibodies (which it refers to as DART and TRIDENT molecules). It is advancing three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload. Its segment is developing and commercializing monoclonal antibody-based therapeutics.

Share on Social Networks: